DE2739439C2 - - Google Patents
Info
- Publication number
- DE2739439C2 DE2739439C2 DE2739439A DE2739439A DE2739439C2 DE 2739439 C2 DE2739439 C2 DE 2739439C2 DE 2739439 A DE2739439 A DE 2739439A DE 2739439 A DE2739439 A DE 2739439A DE 2739439 C2 DE2739439 C2 DE 2739439C2
- Authority
- DE
- Germany
- Prior art keywords
- virus
- horse
- virions
- vaccine
- inactivated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 claims description 65
- 229960005486 vaccine Drugs 0.000 claims description 30
- 241000283073 Equus caballus Species 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 23
- 210000002845 virion Anatomy 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 210000003754 fetus Anatomy 0.000 claims description 12
- 241000283086 Equidae Species 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 229940031551 inactivated vaccine Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 4
- 239000000568 immunological adjuvant Substances 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 description 13
- 241000699800 Cricetinae Species 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 208000000995 spontaneous abortion Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000002718 aborted fetus Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000699680 Cricetus Species 0.000 description 1
- 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000701148 Equine adenovirus Species 0.000 description 1
- 241000710803 Equine arteritis virus Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001113 coital effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/82—Viral vaccine for equine species, e.g. horses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/722,817 US4083958A (en) | 1976-09-13 | 1976-09-13 | Inactivated equine rhinopneumonitis virus vaccine and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2739439A1 DE2739439A1 (de) | 1978-03-16 |
| DE2739439C2 true DE2739439C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-01-14 |
Family
ID=24903513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19772739439 Granted DE2739439A1 (de) | 1976-09-13 | 1977-09-01 | Verfahren zur herstellung eines impfstoffes |
Country Status (4)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4225582A (en) * | 1979-03-08 | 1980-09-30 | The University Of Illinois Foundation | Vaccine for equine rhinopneumonitis |
| US4483851A (en) * | 1982-08-18 | 1984-11-20 | The University Of Kentucky Research Foundation | Treatment for contagious equine metritis |
| US4600711A (en) * | 1982-08-18 | 1986-07-15 | The University Of Kentucky Research Foundation | Composition for topical and infusion treatment of wounds and burns |
| US5084271B1 (en) * | 1984-09-11 | 1997-08-05 | Univ Melbourne | Vaccine for equine herpesvirus |
| US4841023A (en) * | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
| US5853715A (en) * | 1996-08-16 | 1998-12-29 | Bayer Corporation | Cross-protective equine herpesvirus preparations and method of making and using the same |
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1692043C3 (de) * | 1968-03-06 | 1979-04-12 | Behringwerke Ag, 3550 Marburg | Rhinopneumonitis-Vaccine und Verfahren zu deren Herstellung |
-
1976
- 1976-09-13 US US05/722,817 patent/US4083958A/en not_active Expired - Lifetime
-
1977
- 1977-08-31 GB GB36378/77A patent/GB1538704A/en not_active Expired
- 1977-08-31 FR FR7726509A patent/FR2364034A1/fr active Granted
- 1977-09-01 DE DE19772739439 patent/DE2739439A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2364034B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-06-12 |
| GB1538704A (en) | 1979-01-24 |
| US4083958A (en) | 1978-04-11 |
| FR2364034A1 (fr) | 1978-04-07 |
| DE2739439A1 (de) | 1978-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69620402T2 (de) | Prrs-virus-lebendimpfstoffe mit geringer pathogenitaet und verfahren zu deren herstellung | |
| DE69518316T2 (de) | Modifizierter,verbesserter,lebender brsv impfstoff | |
| DE69426051T2 (de) | Impfstoff für Geflügel | |
| DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
| CH617588A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69923470T2 (de) | Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion | |
| DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE2713371C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2739439C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE1617940A1 (de) | Zellstaemme | |
| DE3853736T2 (de) | Staupevirus-Impfstoff. | |
| DE2423129A1 (de) | Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzine | |
| DE69835424T2 (de) | Boviner atmungs- und darmcoronavirus als impfstoff | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
| DE3784397T2 (de) | Lebendvaccine fuer ansteckungskrankheiten von kueken. | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE68927380T2 (de) | Impfstoff | |
| EP0223915B1 (de) | Lebendimpfstoff gegen Mumps und Verfahren zu dessen Herstellung | |
| CH618091A5 (en) | Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine | |
| DE69737198T2 (de) | Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung | |
| DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
| DE2805311A1 (de) | Respiratorische synzytial-vakzine | |
| DE2328579A1 (de) | Varicella-vaccine | |
| DE2121237C3 (de) | Verwendung einer Zellinie zur Züchtung von Viren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |